PDS Biotechnology Q1 2024 Earnings Report
Key Takeaways
PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, compared to a net loss of $9.7 million for the same period in 2023. R&D expenses increased to $6.7 million, and the company announced positive, updated data from its Phase 2 VERSATILE-002 clinical trial.
Reported a net loss of $10.6 million, or $0.30 per share.
R&D expenses increased to $6.7 million due to higher clinical study and medical affairs costs.
Announced updated results from the VERSATILE-002 Phase 2 trial, showing promising outcomes in HNSCC patients.
Strengthened management with the addition of Stephan Toutain as Chief Operating Officer.
PDS Biotechnology
PDS Biotechnology
Forward Guidance
PDS Biotechnology plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC).